Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice

Molecular Psychiatry

Volumn 14, Issue 5, 2009, Pages 511-522

  O'Connor, J C ^a   Lawson, M A ^a   Andre C ^b   Moreau, M ^b   Lestage, J ^b   Castanon, N ^b   Kelley, K W ^a   Dantzer, R ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b CNRS   (France)

Author keywords

1 methyltryptophan; Forced swim test; Kynurenine; Minocycline; Tail suspension test; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; LIPOPOLYSACCHARIDE; MINOCYCLINE; N METHYLTRYPTOPHAN; SEROTONIN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATABOLISM; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; FORCED SWIMMING TEST; IMMOBILIZATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; TRYPTOPHAN METABOLISM;

ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKININS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HINDLIMB SUSPENSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; MINOCYCLINE; MOTOR ACTIVITY; SWIMMING; TIME FACTORS; TRYPTOPHAN;

EID: 65349135346     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002148     Document Type: Article

References (54)

1. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58: 175-189.
2. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17(Suppl 1): S119-S124.
3. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-652.
4. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production, tryptophan degradation, and mental depression-what is the link? Brain Behav Immun 2002; 16: 590-595.
5. Takikawa O, Tagawa Y, Iwakura Y, Yoshida R, Truscott RJ. Interferon-gamma-dependent/independent expression of indolea- mine 2,3-dioxygenase. Studies with interferon- gamma-knockout mice. Adv Exp Med Biol 1999; 467: 553-557.
6. Popov A, Abdullah Z, Wickenhauser C, Saric T, Driesen J, Hanisch FG et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest 2006; 116: 3160-3170.
7. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen- activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem (Tokyo) 2006; 139: 655-662.
8. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468-473.
9. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711: 163-174.
10. Frenois F, Moreau M, O'Connor J, Lawson M, Micon C, Lestage J et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007; 32: 516-531.
11. Moreau M, Lestage J, Verrier D, Mormede C, Kelley KW, Dantzer R et al. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J Infect Dis 2005; 192: 537-544.
12. Booij L, Van der Does AJ, Riedel WJ. Monoamine depletion in psychiatric and healthy populations: review. Mol Psychiatry2003; 8: 951-973.
13. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005; 49: 15-23.
14. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood- brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991; 56: 2007-2017.
15. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000.
16. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon- alpha- induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-544.
17. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem 2007; 282: 15208-15216.
18. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95: 15769-15774.
19. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 14669-14674.
20. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78.
21. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-1870.
22. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10: 1088-1094.
23. Ueno A, Cho S, Cheng L, Wang J, Hou S, Nakano H et al. Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin down-regulates autoimmune diabetes. Diabetes 2007; 56: 1686-1693.
24. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005; 19: 1347-1349.
25. Mormede C, Palin K, Kelley KW, Castanon N, Dantzer R. Conditioned taste aversion with lipopolysaccharide and peptido-glycan does not activate cytokine gene expression in the spleen and hypothalamus of mice. Brain Behav Immun 2004; 18: 186-200.
26. Lestage J, Verrier D, Palin K, Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 2002; 16: 596-601.
27. Porsolt RD. Animal models of depression: utility for transgenic research. Rev Neurosci 2000; 11: 53-58.
28. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP- treated mice. Neurobiol Dis 2007; 26: 36-46.
29. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293: 2003-2011.
30. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005; 115: 71-83.
31. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122: 81-89.
32. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW et al. Cytokine- induced sickness behavior. Brain Behav Immun 2003; 17(Suppl 1): S112-S118.
33. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-54.
34. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25: 154-159.
35. Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen- activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 2006; 96: 314-323.
36. Robinson CM, Hale PT, Carlin JM. NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha. Cytokine 2006; 35: 53-61.
37. Cady SG, Sono M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)- DL-alanine (the oxygen analog of tryptophan), and beta-[3- benzo(b)thienyl]-DL- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991; 291: 326-333.
38. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193.
39. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 129: 186-196.
40. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-1274.
41. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774.
42. Sanni LA, Thomas SR, Tattam BN, Moore DE, Chaudhri G, Stocker R et al. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and non cerebral malaria. Am J Pathol 1998; 152: 611-619.
43. Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru- Lamoury J, Brew BJ. Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 2003; 527: 167-176.
44. Dunn AJ, Chuluyan HE. Endotoxin elicits normal tryptophan and indolamine responses but impaired catecholamine and pituitary- adrenal responses in endotoxin- resistant mice. Life Sci 1994; 54: 847-853.
45. Lacosta S, Merali Z, Anisman H. Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic -like effects. Brain Res 1999; 818: 291-303.
46. Swiergiel AH, Dunn AJ. Feeding, exploratory, anxiety- and depression-related behaviors are not altered in interleukin-6- deficient male mice. Behav Brain Res 2006; 171: 94-108.
47. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology2006; 31: 2121-2131.
48. Lapin IP. Kynurenines as probable participants of depression. Pharmakopsychiatr Neuropsychopharmakol 1973; 6: 273-279.
49. Mangoni A. The 'kynurenine shunt' and depression. Adv Biochem Psychopharmacol 1974; 11: 293-298.
50. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004; 4: 12-17.
51. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2005; 2: 249-260.
52. Deak T, Bellamy C, D'Agostino LG, Rosanoff M, McElderry NK, Bordner KA. Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide. Behav Brain Res 2005; 160: 125-134.
53. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy 2006; 26: 515-521.
54. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 2007; 46: 203-211.